<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02109302</url>
  </required_header>
  <id_info>
    <org_study_id>C12-32</org_study_id>
    <secondary_id>2012-A01055-38</secondary_id>
    <nct_id>NCT02109302</nct_id>
  </id_info>
  <brief_title>Primary Premature Ejaculation Genetics</brief_title>
  <official_title>Identification Des Bases moléculaires de l'éjaculation prématurée Primaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <brief_summary>
    <textblock>
      The main objective of our study is to identify the first genetic etiology of primary&#xD;
      Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism&#xD;
      conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some&#xD;
      patients. To this end, we plan to establish a collection of biological samples and a database&#xD;
      of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This&#xD;
      will lead to improvements in the biological understanding, the &quot;knowledge&quot; of physicians of&#xD;
      the disease, and should improve the patients' quality of life. Not all PE cases have the same&#xD;
      physiopathology and treatment efficiency, which depend on the specific mechanism involved in&#xD;
      the clinical context. Our work will make it possible to develop new therapeutic approaches&#xD;
      suitable for a large proportion of individuals presenting PE. This integrative approach&#xD;
      combining researchers, patients and ethics committees will facilitate profound reflection,&#xD;
      promoting the creation of suitable structures capable of receiving patients for appropriate&#xD;
      consultations. This unique study of PE should also favor industrial partnerships.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2.1 Main Objective&#xD;
&#xD;
        -  To identify the molecular basis of primary premature ejaculation (PPE) in humans for the&#xD;
           development of new adapted therapy.&#xD;
&#xD;
        -  Check and confirm the genetic hypothesis of PPE to fill the void of genetic knowledge&#xD;
           about this syndrome.&#xD;
&#xD;
        -  Improve knowledge of physicians on this disease to increase the comfort of life of&#xD;
           patients.&#xD;
&#xD;
      2.2 Secondary Objectives&#xD;
&#xD;
        -  Provide the basis for new therapeutic approaches.&#xD;
&#xD;
        -  Expanded knowledge of the aetiology of PE and allow better management of patients.&#xD;
&#xD;
        -  Develop strategies to prevent the consequences, sometimes severe , of this condition on&#xD;
           the intimate, personal, social and professional life of these patients. Because all the&#xD;
           PE do not have the same pathophysiology and treatment success depends on its relevance&#xD;
           to the specific mechanism of the clinical form concerned.&#xD;
&#xD;
        -  Increase the comfort of life of the patients.&#xD;
&#xD;
        -  Eliminate public prejudice based on misconceptions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with genetic mutations of susceptibility to primary PE</measure>
    <time_frame>4 years</time_frame>
    <description>We will perform WES (Whole Exome Sequencing) to identify shared defective genes in 20 patients. In case of genetic uniformity and of a genetically homogeneous recruitment, we hope to highlight such a gene in several individuals. As primary PE are very rare, this group should have defective genes at much higher frequencies than in the control population (NCBI, 1000 genome and housing-genome). This will allow us to identify genetic mutations of susceptibility to primary PE.</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Premature Ejaculation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. . Patients (index cases ) Prospective and retrospective cases&#xD;
&#xD;
               -  Man aged over 18 years&#xD;
&#xD;
               -  signing the informed consent&#xD;
&#xD;
               -  Presenting primary PE&#xD;
&#xD;
               -  have an affiliation to a social security system&#xD;
&#xD;
          2. . Related&#xD;
&#xD;
               -  Male or female over 18 years&#xD;
&#xD;
               -  be related to the index case&#xD;
&#xD;
               -  signing the informed consent&#xD;
&#xD;
               -  have an affiliation to a social security system&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          1. . Patients ( index case ) :&#xD;
&#xD;
               -  Be aged under 18&#xD;
&#xD;
               -  have known genetic variations that predispose or can promote psychological&#xD;
                  disorders that can lead to PE ( eg: Kallman 's Syndrome , micropenis , testicular&#xD;
                  dysgenesis , Klinfelter syndrome, Leydig cell hypoplasia )&#xD;
&#xD;
               -  have had psycho- social and psycho- traumatic factors in childhood&#xD;
&#xD;
               -  Inability to receive clear information on the protocol&#xD;
&#xD;
               -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
               -  Major Person subject of legal protection or unable to consent&#xD;
&#xD;
               -  Refusal to be informed of an abnormality detected after genetic testing&#xD;
&#xD;
               -  History of allergies to lidocaine or other anesthetic agent used during puncture&#xD;
                  or blood sample&#xD;
&#xD;
          2. . Related :&#xD;
&#xD;
               -  Age &lt;18 years&#xD;
&#xD;
               -  Inability to receive clear information about the protocol . Unable to participate&#xD;
                  in the entire study.&#xD;
&#xD;
               -  No coverage by the social security system&#xD;
&#xD;
               -  Absence of signature of consent or refusal of the related party&#xD;
&#xD;
               -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
               -  Major Person subject of legal protection or unable to consent&#xD;
&#xD;
               -  Refusal to be informed of a genetic abnormality detected&#xD;
&#xD;
               -  History of allergies to lidocaine or other anesthetic agent used during puncture&#xD;
                  or blood sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Alcaïs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Vogt</last_name>
    <phone>+33 (0)1 42 75 43 20</phone>
    <email>guillaume.vogt@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Polyclinique de Blois</name>
      <address>
        <city>La Chaussée Saint Victor</city>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoît Vogt, MD</last_name>
      <email>benoitvogt@free.fr</email>
    </contact>
    <investigator>
      <last_name>Benoît Vogt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Porto, MD</last_name>
      <email>robert.porto@worldonline.fr</email>
    </contact>
    <investigator>
      <last_name>Robert Porto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Alcaïs, MD</last_name>
      <email>alexandre.alcais@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre Alcaïs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Porto R, Giuliano F. [Premature ejaculation]. Prog Urol. 2013 Jul;23(9):647-56. doi: 10.1016/j.purol.2013.01.005. Epub 2013 Mar 1. Review. French.</citation>
    <PMID>23830259</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

